APP and Alzheimer disease: Since the suppression of the production of Aβ in the AβPP proteolytic pathway (by verubecestat or other BACE1 inhibitors) had no effect on progression of the disease [49,50] either, it follows that in AD, Aβ is produced independently of AβPP and is retained intraneuronally.